3H Medi Solution (former CROee Inc), Japan, through a comprehensive interaction with  associate organizations, such as University Hospital Clinical and Translational Research Center, has had a chance to delve into the existing challenges and future goals of the organization. One of the most important deliberations, pharmaceuticals and researchers, alike need to understand is the process of research screening that plays a pivotal role in deciding what early stage research translates into clinical trials and bedside applications. For any clinical research organization this is the deciding factor for selecting the Seeds for developing into the therapeutic treatments to be offered to its prospective patients that ensure both clinical and commercial viability of the treatments from an organizational point of view. According to 3H Medi Solution the four most important criteria for early stage Screening and subsequently how 3H wishes to facilitate these principles is as follows:

Intellectual Property: 3H estimates that in order to translate a research into bedside application, commercialization is extremely essential, which in turn is possible only if it projects the potential of an adequately strong patent. However many a times, the research details of a drug or therapies are publicly presented at medical conferences and seminars even without applying for a patent prior to such conferences. This is mainly due to ignorance of the researcher and also their inaccessibility to patent processes. Unfortunately, this renders such research with little or no value from patent ownership perspective and thereby discourages clinical research organizations and pharmaceuticals alike from backing up the development of such drugs and therapies, even if they have the potential to be the next panacea. 3H, in collaboration with University Hospital plans at providing support and guidance to such research units to ensure research with potentially sufficient patents and protection from plagiarism

Scope for Development: 3H looks at the scope of development of any research as the next key factor for selection of a Seed for further development into clinical applications. In spite of a research having a promising concept, possibilities of several developmental impediments pushes it low on the priority scale of commercial and research organizations. Likewise, a Seed which has already secured commercial support for development is evaluated by 3H to have a high Research and Development (R & D) prospects. One of the key services offered by 3H is to align such commercial support from corporate and pharmaceuticals to promising researches to create impediment-free developmental scope and clinical trials.

Social Significance: 3H perceives the social significance of the research playing a deciding role in its further developmental prospects. For example, research organization cites drugs for rare diseases as unattractive to  corporate and pharmaceutical  establishments because of their low profit margin yields. Their social and altruistic values are ignored due to their commercial unavailability.  3H advocates for research work in rare diseases as a domain calling for academic commitments by institutions. 3H sincerely supports the ideologies of organizations which assigns fairly high priority to such research that is likely to produce socially valuable outcomes and also calls out to pharmaceutical giants to support the same.

Scientific Value: 3H, in accordance with the other stated factors, also gives high weightage to the scientific value of a research. Originality is valued in all fields including Clinical Research  domain. Unprecedented research is favorably evaluated if it demonstrates the possibility to result in the development of drugs that has the capacity to function in absolutely novel ways. One of 3H main goal is to identify and promote such researches through their various service expertise in the arena of clinical research and trials. 3H Medi Solution sums this discussion by assuring to provide its relevant and unwavering services and support to promote and facilitate the organizational goals, both commercial and altruistic, of all  clinical research organizations and pharmaceuticals, with  current and prospective association with 3H, by leveraging its strong presence and long standing network in the space of clinical research and trials.

For further queries, please feel free to connect with Imran of 3H Medi Solution Japan at imran@3h-ms.co.jp